CD19 and non-Hodgkin lymphoma: CD19-specific chimeric antigen receptor (CAR)-T cells have showed remarkable efficacy in NHL, and three cell products are currently approved by the Food and Drug Administration in the treatment of relapsed or refractory (RR) DLBCL: axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel).